Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Commentary : missing targets on drugs-related deaths, and a Scottish paradox

Bird, Sheila M and Hutchinson, Sharon J. and Hay, Gordon and King, Ruth (2010) Commentary : missing targets on drugs-related deaths, and a Scottish paradox. International Journal of Drug Policy, 21 (3). pp. 155-159. ISSN 0955-3959

[img]
Preview
Text (strathprints013372)
strathprints013372.pdf
Accepted Author Manuscript

Download (133kB) | Preview

Abstract

The 10-year drug strategy for England and Wales was published in February 2008. It dropped drugs-related deaths (DRDs) as a key performance indicator. Scotland retained a necessary strong focus on DRDs. Scotland's DRDs numbered 1006 in 2000–02 and 1009 in 2003–05. The previous Scottish administration's claim that its number of current injectors had decreased substantially between 2000 and 2003 implied, paradoxically, that their DRD rate would have to have increased. Worse was to come: Scotland's DRDs had increased to 876 in 2006 + 2007. We analyse UK's DRDs by sex and age-group to reveal temporal trends (2000–02 versus 2003–05 versus 2006 + 2007) with different public health and epidemiological implications. We also address the above Scottish paradox and assess, by age-group, how consistent Scotland's 876 DRDs in 2006 + 2007 are with Scottish injectors’ DRD rate in 2003–05 of around 1 per 100 injector-years. Public health success in the UK in reducing DRDs at younger ages should not be overshadowed by the late consequence in terms of older-age DRDs of UK's injector epidemics; in the early 1980s in Scotland, and late 1980s in England and Wales. Targets for reducing DRDs should pay heed to UK's injector epidemics.